���构特征与受体作用机制 — Research Overview

By Editorial Desk · published 2025-10-27 · last reviewed 2025-11-29 · Guide

Everything below concerns lyophilization. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-11-29. Where a claim depends on a specific study, the study is described rather than over-claimed.

结构特征与受体作用机制

皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。

序列层面的改动同时解决了两个问题，即酶解稳定性与肾脏清除速度。天然 GLP-1 在循环中的半衰期仅约两分钟，主要被二肽基肽酶-4 迅速灭活。酰化侧链与白蛋白的可逆结合形成循环储库，使分子缓慢释放并持续激活受体。这种设计思路后来被广泛用于同类长效肽的开发，属于该类药物化学改造的典型范式。

Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。

Semaglutide Background and Drug Class

Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.

GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.

Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.

Semaglutide at a glance

Handling, Storage, and Characterization

Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.

Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.

Related pages on this site

• Smart toolkit
• Modern workbook
• Standard handbook
• Regional digest
• Robust digest
• Modern workbook
• Automated index
• Lightweight overview

Background and Receptor Mechanism

Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.

The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.

Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.

Notes from published material

== Medical uses == Insulin degludec is indicated to improve glycemic control in people with diabetes. In a meta-analysis involving data from 3 randomized controlled trials having 1171 patients, thrice weekly insulin degludec had similar efficacy as daily insulin glargine injections with regards to the fasting blood glucose reduction, having similar safety and risk of low blood glucose (hypoglycaemia) profile. However the overall HbA1c reduction with thrice weekly insulin degludec injection was marginally lower than that of daily insulin glargine injections. Hence thrice weekly degludec injections can be considered in extremely needle prick phobic patients as a choice for basal insulin therapy.

== Statements by Russian analysts == In August 2008, Pavel Felgenhauer, a Moscow-based analyst of military affairs, wrote in Novaya Gazeta that the Russian plan was for the Ossetians to deliberately provoke the Georgians so that "any response, harsh or soft, would be used as an occasion for the attack". He noted that Russia's invasion of Georgia had been planned in advance, with the final political decision to start the war apparently having been made back in April. The war was planned to start no later than the second half of August, because in the following months the weather would deteriorate. The goal of the war was to expel all Georgians from Abkhazia and South Ossetia, to free Tbilisi from Saakashvili, and to force NATO and Americans to abandon the Caucasus region. If the Georgians had not responded to South Ossetian attacks, then Abkhaz separatists would have started the operation to reclaim the Kodori Gorge. But Saakashvili succeeded in destroying the Ossetian militia and Moscow had no other option rather than to confront Georgia itself openly. Felgenhauer also made similar arguments in another English-language article. He wrote that "The invasion was inevitable, no matter what the Georgians did." Earlier, on 7 August, Felgenhauer claimed that although South Ossetian separatists wanted Russia to intervene, "apparently not everyone in Moscow" was "ready to plunge headlong into war." It was Felgenhauer who predicted in June 2008 that Vladimir Putin would start a war against Georgia in Abkhazia and South Ossetia supposedly in late August 2008.

The project has faced criticism for delays and cost overruns. After multiple delays, the opening date has slipped from an original target of 2023 to a projected completion of construction by end of 2028, with full operations not expected until 2029–2030. Estimated at 200 billion ISK, costs have exceeded all original projections, and critics have questioned the hospital's location as neither central to modern Reykjavík nor likely to ease the city's traffic problems.

Sources: en.wikipedia.org

Further detail

Technology While Minds would likely have different capabilities, especially seeing their widely differing ages (and thus technological sophistication), this is not a theme of the books. It might be speculated that the older Minds are upgraded to keep in step with the advances in technology, thus making this point moot. It is also noted in Matter that every Culture Mind writes its own OS, thus continually improving itself and, as a side benefit, becoming much less vulnerable to outside takeover by electronic means and viruses, as every Mind's processing functions work differently. The high computing power of the Mind is apparently enabled by thought processes (and electronics) being constantly in hyperspace (thus circumventing the light speed limit in computation). Minds do have back-up capabilities functioning with light-speed if the hyperspace capabilities fail – however, this reduces their computational powers by several orders of magnitude (though they remain sentient). The storage capability of a GSV Mind is described in Consider Phlebas as 1030 bytes (1 million yottabytes). The Culture is a society undergoing slow (by present-day Earth standards) but constant technological change, so the stated capacity of Minds is open to change. In the last 3,000 years, the capacity of Minds has increased considerably. By the time of the events of the novel Excession in the mid 19th century, Minds from the first millennium BCE are referred to jocularly as minds, with a small 'm'.

The Bio-medical Waste (Management and Handling) Rules, 1998 and further amendments were passed for the regulation of bio-medical waste management. On 28 March 2016 Biomedical Waste Management Rules (BMW 2016) were also notified by Central Govt. Each state's Pollution Control Board or Pollution control Committee will be responsible for implementing the new legislation. New regulations affect the distribution of medical waste by medical professionals into their proper receptacles. Due to the competition to improve quality and so as to get accreditation from agencies like ISO, the NABH, JCI, and many private organizations have initiated proper biomedical waste disposal but still the gap is huge. Many studies took place in Gujarat, India regarding the knowledge of workers in facilities such as hospitals, nursing homes, or home health. It was found that 26% of doctors and 43% of paramedical staff were unaware of the risks related to biomedical wastes. After extensively looking at the different facilities, many were undeveloped in the area regarding biomedical waste. The rules and regulations in India work with The Bio-medical Waste (Management and Handling) Rules from 1998, yet a large number of health care facilities were found to be sorting the waste incorrectly. The National Green Tribunal (NGT) has been stringent on the application of the BMW 2016 over the past 12 months. There are now over 200 licensed Common Bio Medical Waste Treatment and Disposal Facilities (CBWTDF) or Common Treatment Facility (CTF) in the country.

The key intermediate, normeperidine, is obtained by a scheme closely akin to the parent molecule. Thus, alkylation of benzyl cyanide (1) with the tosyl analog of the bischloroethylamine (2) leads to the substituted piperidine (3). Basic hydrolysis serves to convert the nitrile to the acid (4). Treatment of this last with sulfuric acid in ethanol serves both to esterify the acid and to remove the tosyl group to yield the secondary amine (5). Alkylation of that amine by means of N-(2-chloroethyl)morpholine gives morpheridine.

In 2024, McGregor and Boorman – with their principal support crew from the previous Long Way journeys – undertook a fourth international trip, this time on a 1974 Moto Guzzi Eldorado police motorcycle, while Boorman chose a BMW R75/5. This was documented in the 2025 series Long Way Home.

Sources: en.wikipedia.org

Frequently asked questions